GDNF therapy for Parkinson's disease (Q37203371)

18 August 2017

1 reference

title

GDNF therapy for Parkinson's disease (English)

1 reference

18 August 2017

1 reference

1

Murray Hong

1 reference

18 August 2017

2

Karim Mukhida

1 reference

18 August 2017

3

Ivar Mendez

1 reference

18 August 2017

1 July 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

1125-1139

1 reference

18 August 2017

7

1 reference

Parkinsonism: onset, progression, and mortality

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

The functional anatomy of basal ganglia disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Parkinson's disease: a major hypokinetic basal ganglia disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

The cellular pathology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Parkinson's disease: management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Management of non-motor symptoms in advanced Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Cognitive dysfunction and dementia in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Cognitive impairment in Parkinson's disease and dementia with lewy bodies: a spectrum of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Advances in the pharmacologic management of early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Levodopa: is toxicity a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Pharmacologic profile of ropinirole: a nonergoline dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Clinical trials with rasagiline: evidence for short-term and long-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Long-term follow-up results of selective VIM-thalamotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Posteroventral medial pallidotomy in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Unilateral subthalamotomy in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD--a comparison of neuropsychological effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Behavioural disorders, Parkinson's disease and subthalamic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Protection from 1-methyl-4-phenylpyridinium (MPP+) toxicity and stimulation of regrowth of MPP(+)-damaged dopaminergic fibers by treatment of mesencephalic cultures with EGF and basic FGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Intrastriatal injection of sonic hedgehog reduces behavioral impairment in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF family receptor complexes are emerging drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Localized striatal delivery of GDNF as a treatment for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Functional recovery in parkinsonian monkeys treated with GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Dopaminergic neurons protected from degeneration by GDNF gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF in Parkinson disease: an object lesson in the tyranny of type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

GDNF in Parkinson's disease: the perils of post-hoc power

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Factors affecting the clinical outcome after neural transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Cell transplantation in Parkinson's disease: how can we make it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Regulation of the development of mesencephalic dopaminergic systems by the selective expression of glial cell line-derived neurotrophic factor in their targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical con

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: Survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Do patients with Parkinson?s disease benefit from embryonic dopamine cell transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.7.1125

10.1586/14737175.8.7.1125

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18590482